182 related articles for article (PubMed ID: 35243732)
1. COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.
Özgen Z; Aksoy H; Akın Çakıcı Ö; Koku Aksu AE; Erdem O; Kara Polat A; Gürel MS
Dermatol Ther; 2022 May; 35(5):e15417. PubMed ID: 35243732
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.
Róbert L; Kovács A; Sárdy M; Fábián M
Acta Dermatovenerol Croat; 2023 Dec; 31(3):156-157. PubMed ID: 38439728
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.
Calabria E; Canfora F; Mascolo M; Varricchio S; Mignogna MD; Adamo D
Pathol Res Pract; 2022 Apr; 232():153834. PubMed ID: 35278817
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.
Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M
Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960
[TBL] [Abstract][Full Text] [Related]
5. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Uzuncakmak TK; Özkoca D; Askin O; Kutlubay Z
Dermatol Ther; 2021 Jan; 34(1):e14647. PubMed ID: 33296557
[TBL] [Abstract][Full Text] [Related]
6. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
Saleh MA; Saleh NA
Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
[TBL] [Abstract][Full Text] [Related]
7. Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab.
Waldman RA; Creed M; Sharp K; Adalsteinsson J; Imitola J; Durso T; Lu J
J Am Acad Dermatol; 2021 Apr; 84(4):e197-e198. PubMed ID: 33130180
[No Abstract] [Full Text] [Related]
8. Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.
Jafri ZA; Walia S; Ivanic MG; Wu JJ
J Dermatolog Treat; 2022 May; 33(3):1606-1607. PubMed ID: 33375865
[TBL] [Abstract][Full Text] [Related]
9. Treatment with immunosuppressants did not increase the risk of COVID-19 in pemphigus patients: A single-center survey-based study.
Feng X; Zhou X; Zhang X; Xiao Y; Li F; Mi W; Gao J; Wang J; Zhou Y; Wang M; Wang W; Li W
Int Immunopharmacol; 2024 Jun; 135():112307. PubMed ID: 38796966
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.
Sinagra JL; Vedovelli C; Binazzi R; Salemme A; Moro F; Mazzanti C; Didona B; Di Zenzo G
Front Immunol; 2021; 12():665522. PubMed ID: 33936104
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and autoimmune bullous diseases: Lessons learned.
Kasperkiewicz M; Woodley DT
Autoimmun Rev; 2023 Apr; 22(4):103286. PubMed ID: 36738951
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris.
Fenizia C; Moltrasio C; Ottobrini L; Utyro O; Genovese G; Vanetti C; Trabattoni D; Marzano AV
J Invest Dermatol; 2023 Aug; 143(8):1601-1604. PubMed ID: 36716924
[No Abstract] [Full Text] [Related]
14. Treatment of pemphigus patients in the COVID-19 era: A specific focus on rituximab.
Mahmoudi H; Tavakolpour S; Nili A; Salehi Farid A; Daneshpazhooh M; Rashidian M
Dermatol Ther; 2020 Nov; 33(6):e14188. PubMed ID: 32794333
[No Abstract] [Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus.
Hatami P; Balighi K; Nicknam Asl H; Aryanian Z
Dermatol Ther; 2022 Jan; 35(1):e15216. PubMed ID: 34811862
[TBL] [Abstract][Full Text] [Related]
17. Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
Akoglu G
Dermatol Ther; 2022 May; 35(5):e15396. PubMed ID: 35187768
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune skin disorders and SARS-CoV-2 vaccination - a meta-analysis.
Hinterseher J; Hertl M; Didona D
J Dtsch Dermatol Ges; 2023 Aug; 21(8):853-861. PubMed ID: 37218538
[TBL] [Abstract][Full Text] [Related]
19. Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.
Koszegi B; Stone C; Murrell DF
Front Med (Lausanne); 2023; 10():1149742. PubMed ID: 36999066
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Status of Patients with Autoimmune Bullous Diseases (Pemphigus and Bullous Pemphigoids) in Dermatology Clinics of Mashhad University of Medical Sciences During the COVID-19 Pandemic Using Telemedicine.
Mehri Z; Nahidi Y; Ramezani B; Torabi S
Telemed J E Health; 2024 Jun; 30(6):e1742-e1746. PubMed ID: 38416427
[No Abstract] [Full Text] [Related]
[Next] [New Search]
